REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have earned an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $31.63.

Several research analysts have recently commented on RGNX shares. HC Wainwright lowered their price target on REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, March 17th. Leerink Partners set a $24.00 target price on REGENXBIO in a report on Tuesday, March 18th. Morgan Stanley raised their price target on REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, March 14th. Wall Street Zen upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Finally, Raymond James assumed coverage on REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 target price on the stock.

Insider Transactions at REGENXBIO

In related news, Director Kenneth T. Mills sold 20,602 shares of the company’s stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the completion of the sale, the director now directly owns 475,103 shares of the company’s stock, valued at approximately $3,758,064.73. This represents a 4.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 12.79% of the company’s stock.

Institutional Trading of REGENXBIO

Institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC purchased a new position in REGENXBIO in the 1st quarter valued at about $35,000. Brooklyn Investment Group lifted its position in shares of REGENXBIO by 163.7% during the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 3,466 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of REGENXBIO during the fourth quarter worth about $54,000. Dynamic Technology Lab Private Ltd bought a new position in shares of REGENXBIO during the fourth quarter worth about $79,000. Finally, Laurion Capital Management LP bought a new position in shares of REGENXBIO during the fourth quarter worth about $79,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Trading Down 0.5%

NASDAQ RGNX opened at $10.08 on Thursday. The stock has a market capitalization of $505.61 million, a price-to-earnings ratio of -2.00 and a beta of 1.11. REGENXBIO has a twelve month low of $5.04 and a twelve month high of $15.36. The stock has a 50-day moving average of $8.01 and a 200 day moving average of $7.95.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). The company had revenue of $89.01 million during the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. Equities analysts predict that REGENXBIO will post -4.84 EPS for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.